7 withdrawn. 7 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Withdrawn 7 |
| Phase 1 | 2 | Withdrawn 2 |
Follow Amyloidosis: new trials by email Literature Review of Amyloidosis trials Research Report on Amyloidosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE) Venetoclax, Dexamethasone, Daratumumab - AL Amyloidosis, Light Chain (AL) Amyloidosis | Phase 1 / Phase 2 | Withdrawn | Alfred Chung, MD | 2024-01-08 | 2025-03-06 | |
| Isatuximab and Bendamustine in Systemic Light Chain Amyloidosis Bendamustine Hydrochloride, Isatuximab - Amyloidosis, Light Chain (AL) Amyloidosis | Phase 2 | Withdrawn | Tufts Medical Center | 2022-09-01 | 2024-10-18 | |
| ION-682884 in Patients With TTR Amyloid Cardiomyopathy ION 682884 - Transthyretin Amyloid Cardiopathy | Phase 2 | Withdrawn | Brigham and Women's Hospital | 2021-06-01 | 2026-02-20 | |
| Ibrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory Immunoglobulin Light Chain Amyloidosis Bortezomib, Dexamethasone, Ibrutinib - Amyloidosis, Immunoglobulin Light Chain Deposition | Phase 2 | Withdrawn | Mayo Clinic | 2018-03-15 | 2018-03-02 | |
| The Effect of an Antisense Oligonucleotide to Lower Transthyretin (TTR) Levels on the Progression of -Wild-type TTR Involving the Heart Isis 420915/GSK 299872 - Amyloidosis | Phase 2 | Withdrawn | Brigham and Women's Hospital | 2016-01-01 | 2016-08-10 | |
| High Cut-off Hemodialysis in Patients With Advanced Cardiac AL Amyloidosis and End Stage Renal Disease High Cut-off Hemodialysis, Chemotherapy - Primary Amyloidosis of Light Chain Type | Phase 2 | Withdrawn | Fondazione IRCCS Policlinico San Matteo di Pavia | 2015-02-01 | 2018-03-21 | |
| Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies Edetate Calcium Disodium, Ethanol, Trimethoprim-sulfamethoxazole - Chronic Myeloproliferative Disorders, Infection | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2013-02-15 |
Immunoglobulin Light-chain Amyloidosis (3) · Blast Crisis (1) · Burkitt Lymphoma (1) · Cardiomyopathies (1) · Congenital Abnormalities (1) · Hodgkin Disease (1) · Immunoblastic Lymphadenopathy (1) · Infections (1) · Intraocular Lymphoma (1) · Leukemia (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Hairy Cell (1) · Leukemia, Large Granular Lymphocytic (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1)
Metabolic Diseases (7) · Nutritional and Metabolic Diseases (7) · Proteostasis Deficiencies (7) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Paraproteinemias (3) · Cardiovascular Diseases (2) · Lymphoproliferative Disorders (2) · Neoplasms, Plasma Cell (2) · Blood Coagulation Disorders (1) · Blood Platelet Disorders (1) · Blood Protein Disorders (1)
Calcium Dobesilate (2) · Dexamethasone (2) · Bendamustine Hydrochloride (1) · Biological Assay (1) · Bortezomib (1) · Drug Therapy (1) · Edetic Acid (1) · Ethanol (1) · In Situ Hybridization (1) · In Situ Hybridization, Fluorescence (1) · Oligonucleotides, Antisense (1) · Pentetic Acid (1) · Saline Solution (1) · Saline Solution, Hypertonic (1) · Sodium Chloride (1)
Brigham and Women's Hospital (2) · Alfred Chung, MD (1) · Fondazione IRCCS Policlinico San Matteo di Pavia (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · Tufts Medical Center (1)
Italy (1) · United States (1)
Alfred Chung, MD (1) · Cindy Varga, MD (1) · Jorge Cortes, MD (1) · Patrick Chaftari, MD (1) · Rodney H Falk (1) · Rodney H Falk, MD (1) · Taimur Sher (1)
P30CA015083 (1)